171 related articles for article (PubMed ID: 37467042)
1. Reinfection incidence and risk among people treated for recent hepatitis C virus infection.
Martinello M; Carson JM; Van Der Valk M; Rockstroh JK; Ingiliz P; Hellard M; Nelson M; Lutz T; Bhagani S; Kim AY; Hull M; Cordes C; Moon J; Feld JJ; Gane E; Rauch A; Bruneau J; Tu E; Applegate T; Grebely J; Dore GJ; Matthews GV;
AIDS; 2023 Oct; 37(12):1883-1890. PubMed ID: 37467042
[TBL] [Abstract][Full Text] [Related]
2. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study.
Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B;
Clin Infect Dis; 2022 Nov; 75(10):1809-1819. PubMed ID: 35362522
[TBL] [Abstract][Full Text] [Related]
4. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
[TBL] [Abstract][Full Text] [Related]
5. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units.
Valencia J; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Morro A; Alvarez J; Pulido L; Cañamares I; Escobar I; Moreno S; Ryan P
Int J Drug Policy; 2019 Oct; 72():181-188. PubMed ID: 31253391
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
[TBL] [Abstract][Full Text] [Related]
7. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression.
Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua NZ; Fierer DS; Chromy D; Rockstroh JK; Martin TCS; Ingiliz P; Hung CC; Dore GJ; Martinello M; Matthews GV
Lancet HIV; 2022 Jun; 9(6):e414-e427. PubMed ID: 35659336
[TBL] [Abstract][Full Text] [Related]
8. Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs.
Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J
Clin Infect Dis; 2021 Apr; 72(8):1392-1400. PubMed ID: 32166305
[TBL] [Abstract][Full Text] [Related]
9. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C
Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704
[TBL] [Abstract][Full Text] [Related]
10. Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era.
Ingiliz P; Wehmeyer MH; Boesecke C; Schulze Zur Wiesch J; Schewe K; Lutz T; Baumgarten A; Simon KG; Hueppe D; Rockstroh JK; Mauss S; Christensen S; ;
Clin Infect Dis; 2020 Aug; 71(5):1248-1254. PubMed ID: 31562816
[TBL] [Abstract][Full Text] [Related]
11. Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study.
Carson JM; Barbieri S; Cunningham E; Mao E; van der Valk M; Rockstroh JK; Hellard M; Kim A; Bhagani S; Feld JJ; Gane E; Thurnheer MC; Bruneau J; Tu E; Dore GJ; Matthews GV; Martinello M;
J Int AIDS Soc; 2023 Sep; 26(9):e26168. PubMed ID: 37675828
[TBL] [Abstract][Full Text] [Related]
12. Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England.
Hibbert M; Simmons R; Harris H; Desai M; Sabin CA; Mandal S
J Viral Hepat; 2023 Aug; 30(8):646-655. PubMed ID: 36929670
[TBL] [Abstract][Full Text] [Related]
13. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
[TBL] [Abstract][Full Text] [Related]
14. Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta-analysis.
Munari SC; Traeger MW; Menon V; Latham NH; Manoharan L; Luhmann N; Baggaley R; MacDonald V; Verster A; Siegfried N; Conway B; Klein M; Bruneau J; Stoové MA; Hellard ME; Doyle JS
Liver Int; 2023 Dec; 43(12):2625-2644. PubMed ID: 37817387
[TBL] [Abstract][Full Text] [Related]
15. Sexually-transmitted hepatitis C virus reinfections among people living with HIV in Taiwan: the emerging role of genotype 6.
Chen GJ; Sun HY; Chang SY; Su LH; Chen YT; Hsieh SM; Liu WD; Sheng WH; Huang YS; Lin KY; Su YC; Liu WC; Hung CC
Emerg Microbes Infect; 2022 Dec; 11(1):1227-1235. PubMed ID: 35412439
[TBL] [Abstract][Full Text] [Related]
16. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
[TBL] [Abstract][Full Text] [Related]
17. Incidence and Risk Factors of Reinfection with HCV after Treatment in People Living with HIV.
Cheng CY; Ku SY; Lin YC; Chen CP; Cheng SH; Lin IF
Viruses; 2022 Feb; 14(2):. PubMed ID: 35216032
[TBL] [Abstract][Full Text] [Related]
18. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
[TBL] [Abstract][Full Text] [Related]
19. High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results From the TraP Hep C Program-A Prospective Nationwide, Population-Based Study.
Johannesson JM; Fridriksdottir RH; Löve TJ; Runarsdottir V; Hansdóttir I; Löve A; Thordardottir M; Hernandez UB; Olafsson S; Gottfredsson M;
Clin Infect Dis; 2022 Nov; 75(10):1732-1739. PubMed ID: 35438144
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C Virus Reinfection in a Real-World Cohort of Homeless-Experienced Individuals in Boston.
Beiser ME; Shaw LC; Shores SK; Carson JM; Hajarizadeh B
Clin Infect Dis; 2023 Jul; 77(1):46-55. PubMed ID: 36869823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
